MoleSafe USA Announces Appointment of Mark Kaufmann, MD, as Chief Medical Officer

FLORHAM PARK, N.J., March 27, 2019 /PRNewswire/ -- MoleSafe USA LLC, the provider of the SKIN SURVEILLANCE PROGRAM (SSP) - the world's leading skin surveillance program for the early detection of skin cancer, today announced Mark Kaufmann, MD, associate clinical professor in the department of dermatology at the Icahn School of Medicine at Mount Sinai in New York, as chief medical officer (CMO). Kaufmann was in private practice for 23 years and, until recently, served on the board of directors of the American Academy of Dermatology and continues to be active on many academy committees, including as an advisor to the Academy RUC team.

"Dr. Kaufmann brings substantial clinical leadership to MoleSafe. The MoleSafe Skin Surveillance Program (SSP) has provided full-body screenings to over 300,000 patients worldwide and is used by over 600 dermatologists across the United States. MoleSafe is executing on a national expansion in partnership with dermatologists and primary care providers, making the SSP available to over 50 million individuals at risk of skin cancer across the nation," says Kevin Sheridan, CEO MoleSafe. "Dr. Kaufmann has been highly instrumental within the field of dermatology and we look forward to expanding the depth of our operations with his guidance and knowledge."

"At MoleSafe, we pride ourselves on being an innovative, caring company that makes life-saving skin surveillance technology available to all those at risk of skin cancer. Our goal is to protect and improve their quality of life," says Dr. Mark D. Kaufmann, CMO. "There are over 1,250,000 individuals who have been diagnosed with melanoma in the USA and millions who are considered high risk for melanoma. Our world-class SSP combines total-body photography, with clinical and dermoscopic imaging of atypical moles/lesions, allowing MoleSafe to more accurately distinguish between benign lesions that require clinical follow-up and those suspicious enough to warrant a biopsy. Most importantly, the evaluation is undertaken by a team of board-certified dermatologists who are pigmented lesion experts."

"My vision for MoleSafe is to work with dermatologists and primary care physicians to make the MoleSafe SSP available to the millions of patients that have been diagnosed with skin cancer or are at high risk of developing skin cancer. Early detection not only saves lives but will lower overall healthcare costs," remarks Kaufmann.

In addition to receiving his M.D. from New York University and completing his dermatology residency at Albert Einstein College Hospital, Dr. Kaufmann's contributions to the American Academy of Dermatology have been recognized by his receiving a Presidential Citation in 2013, 2014, 2015 and 2017.

MoleSafe USA

MoleSafe is the leader in advanced skin screening diagnostic services through our exclusive Skin Surveillance Program (SSP). Combining the latest technology in total-body photography, serial digital dermoscopic imaging (SDDI) and expert diagnosis by world-renowned dermatologists, the SSP has the accuracy to reveal changes in a patient's skin to detect skin cancer at the earliest possible stage for fast, effective treatment. For more information about MoleSafe, please see www.molesafe.com.

PRESS CONTACT: 

KEVIN SHERIDAN, CEO, MoleSafe USA
[email protected]
Office: 1-877-665-3723
Direct: 908-838-0339
Cell: 973-432-2725
www.molesafe.com
www.molesafeUSA.com

Related Images

dr-mark-kaufmann-md.jpg
Dr. Mark Kaufmann, MD

molesafe-logo.jpg
MoleSafe Logo

molesafe.jpg
MoleSafe

Related Links

MoleSafe website

MoleSafe USA website

SOURCE MoleSafe USA LLC

Related Links

http://www.molesafeUSA.com